MedPath

RAY-1225

Generic Name
RAY-1225

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Phase 3
Not yet recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2025-03-25
Last Posted Date
2025-03-25
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
640
Registration Number
NCT06893016
Locations
🇨🇳

Peking University People's Hospital, Beijing, China

A Study of RAY1225 in Participants With Impaired Kidney Function

Phase 1
Completed
Conditions
Kidney Impairment
Interventions
First Posted Date
2024-09-26
Last Posted Date
2025-03-05
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
32
Registration Number
NCT06613763
Locations
🇨🇳

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China

A Study of RAY1225 in Participants With Impaired Liver Function

Phase 1
Recruiting
Conditions
Hepatic Impairment
Interventions
First Posted Date
2024-08-29
Last Posted Date
2025-03-19
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
24
Registration Number
NCT06577415
Locations
🇨🇳

Nanfang Hospital,South Medical Hospital, Guangzhou, Guangdong, China

A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-08-29
Last Posted Date
2025-03-19
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
48
Registration Number
NCT06577428
Locations
🇨🇳

Guangdong Hospital of Chinese Medicine, Guanzhou, Guangdong, China

A Study of RAY1225 in Participants With Obesity

Phase 2
Recruiting
Conditions
Obesity
Interventions
Drug: Placebo
First Posted Date
2024-02-12
Last Posted Date
2025-03-19
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
270
Registration Number
NCT06254261
Locations
🇨🇳

Peking University People's Hospital, Beijing, Hebei, China

A Study of RAY1225 in Participants With Type 2 Diabetes

Phase 2
Recruiting
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Drug: Placebo
First Posted Date
2024-02-12
Last Posted Date
2025-03-05
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
270
Registration Number
NCT06254274
Locations
🇨🇳

Peking University People's Hospital, Beijing, Hebei, China

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Phase 1
Completed
Conditions
Obese
Healthy
Interventions
Drug: Placebo
First Posted Date
2023-04-28
Last Posted Date
2024-08-14
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
68
Registration Number
NCT05835752
Locations
🇨🇳

Nanfang Hospital,South Medical Hospital, Guangzhou, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath